PHOENIX, Oct. 10, 2019 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today provided shareholder updates.
"The third quarter of 2019 was one of the most productive in our company's history," said Donald Dickerson, CFO of Creative Medical Technology Holdings Inc. "We laid out a roadmap for the back half of the year, and I am proud that we have delivered on all fronts."
"I am thrilled with the effort of our team and am confident the fruit of their labor will come to the forefront as we close out the year," commented Timothy Warbington, President and CEO of Creative Medical Technology Holdings, Inc. "I would also like to take a moment to thank our committed shareholders, as we recognize the stock price has not been reflective of the intrinsic value we have built in the company. Please rest assured we remain committed to increasing shareholder value, and believe your patience will be greatly rewarded in the near future."
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTC under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.For more information on our Caverstem® procedure please go to www.caverstem.com.
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.